

テーマA: 「増殖シグナルを標的とした革新的がん治療法探索・開発」

- 1) Tsutsui N., Tanabe G., Ikeda N., Okamura S., Ogawa M., Miyazaki K., Kita A., Sugiura R., Muraoka O.: Structure-activity relationship studies on acremomannolipin A, the potent calcium signal modulator with a novel glycolipid structure 4: Role of acyl side chains on d-mannose. *Eur J Med Chem*, 121: 250-271(2016)
- 2) 杉浦麗子: RNA とエピジェネティクス研究の最前線と疾患治療・創薬の可能性 序文. *日本薬理学雑誌*, 147(6): 339 (2016)
- 3) 佐藤亮介、萩原加奈子、喜多綾子、杉浦麗子: シグナル伝達拠点としての RNA 顆粒の役割～RNA 顆粒によるシグナル伝達分子の空間的制御～. *日本薬理学雑誌*. 147(6): 340-345 (2016)
- 4) 佐藤亮介: シグナル伝達が制御する翻訳開始機構. *日本薬理学雑誌*. 147(6): 368-369 (2016)
- 5) 萩原加奈子: RNA たちの井戸端会議は何をもたらすのか. *日本薬理学雑誌*. 147(6): 370 (2016)
- 6) Ohno H., Minamiguchi D., Nakamura S., Shu K., Okazaki S., Honda M., Misu R., Moriwaki H., Nakanishi S., Oishi S., Kinoshita T., Nakanishi I., Fujii N.: Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors. *Bioorg. Med. Chem.* 24, 1136-1141.(2016) 査読有り
- 7) Tanabe G., Xie W., Balakishan G., F. A. Amer M., Tsutsui N., Takemura H., Nakamura S., Akaki J., Ninomiya K., Morikawa T., Nakanishi I., Muraoka O.: Hydrophobic substituents increase the potency of salacinol, a potent α -glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'. *Bioorg. Med. Chem.* 24, 3705-3715.(2016) 査読有り
- 8) Kaneko H., Nakamura S., Kawashita N.: Practical use of compound-target interaction in chemistry and drug discovery ~A chemoinformatics approach~. *Yakugaku Zasshi*. 136, 95-96.(2016) 査読有り
- 9) 中村真也: 相同性の高いタンパク質に結合する同一化合物の結合様式差の要因検討、*日本化学会情報化学部会誌*, 34, 17-20.(2016) 査読有り
- 10) * Thane M., Loilome W., Techasen A., Sugihara E., Okazaki S., Abe S., Ueda S., Masuko T., Namwat N., Khuntikeo N., Titapum A., Pairojkul C., Saya H., Yongvanit P.: CD44variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for CCA treatment. *Cancer Science* 107, 991-1000 (2016)
- 11) * Tsuchihashi K., Okazaki S., Ohmura M., Sampetean O., Onishi N., Wakimoto H., Yoshikawa M., Seishima R., Iwasaki Y., Morikawa T., Abe S., Takao A., Shimizu M., Masuko T., Nagane M., Furnari F., Akiyama T., Suematsu M., Baba E., Akashi K., Saya H., Nagano O.: The EGF receptors promotes the malignant potential of glioma by regulating amino acid transporter system xc (-). *Cancer Res.* 76, 2954-63.(2016)
- 12) * Okazaki S., Nakatani F., Masuko K., Tsuchihashi K., Ueda S., Masuko T., Saya H., Nagano O.: Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. *Biochem Biophys Res Commun.* 470(1), 239-44. (2016)

- 13) * Kitagawa N., Morikawa T., Motai C., Ninomiya K., Okugawa S., Nishida A., Yoshikawa M., Muraoka O.: The antiproliferative effect of chakasaponins I and II, floratheasaponin A, and epigallocatechin 3-O-gallate isolated from *Camellia sinensis* on human digestive tract carcinoma cell lines. *Int. J. Mol. Sci.*, 17, 1979 (2016) 査読有り
- 14) * Manse Y., Ninomiya K., Nishi R., Kamei I., Katsuyama Y., Imagawa T., Chipecch S., Muraoka O., Morikawa T.: Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from *Alpinia galanga* fruit. *Bioorg. Med. Chem.* 24, 6215-6224 (2016) 査読有り
- 15) * Moriyama H., Moriyama M., Ninomiya K., Morikawa T., Hayakawa T.: Inhibitory effects of oligostilbenoids from the bark of *Shorea roxburghii* on malignant melanoma cell growth: implications for novel topical anticancer candidates. *Biol. Pharm. Bull.* 39, 1675-1682 (2016) 査読有り
- 16) * Morikawa T., Hachiman I., Matsuo K., Nishida E., Ninomiya K., Hayakawa T., Yoshie O., Muraoka O., Nakayama T.: Neolignans from the arils of *Myristica fragrans* as potent antagonists of CC chemokine receptor 3. *J. Nat. Prod.* 79, 2005-2013 (2016) 査読有り
- 17) * Kitagawa N., Ninomiya K., Okugawa S., Motai C., Nakanishi Y., Yoshikawa M., Muraoka O., Morikawa T.: Quantitative determination of principal alkaloid and flavonoid constituents in wintersweet, the flower buds of *Chimonanthus praecox*. *Nat. Prod. Commun.* 11, 953-856 (2016) 査読有り
- 18) * Morikawa T., Kitagawa N., Tanabe G., Ninomiya K., Okugawa S., Motai C., Kamei I., Yoshikawa M., Lee I-J., Muraoka O.: Quantitative determination of alkaloids in lotus flower (flower buds of *Nelumbo nucifera*) and their melanogenesis inhibitory activity. *Molecules* 21, 930 (2016) 査読有り
- 19) * Matsuda H., Nakamura S., Morikawa T., Muraoka O., Yoshikawa M.: New biofunctional effects of the flower buds of *Camellia sinensis* and its bioactive acylated oleanane-type triterpene oligoglycosides. *J. Nat. Med.* 70, 689-701 (2016) Review
- 20) * Ninomiya K., Motai C., Nishida E., Kitagawa N., Yoshihara K., Hayakawa T., Muraoka O., Li X., Nakamura S., Yoshikawa M., Matsuda H., Morikawa T.: Acylated oleanane-type triterpene saponins from the flowers of *Bellis perennis* show anti-proliferative activities against human digestive tract carcinoma cell lines. *J. Nat. Med.* 70, 435-451 (2016) 査読有り
- 21) * Ninomiya K., Shibatani K., Sueyoshi M., Chaipech S., Pongpiriyadacha Y., Hayakawa T., Muraoka O., Morikawa T.: Aromatase inhibitory activity of geranylated coumarins, mammeasins C and D, isolated from the flowers of *Mammea siamensis*. *Chem. Pharm. Bull.* 64, 880-885 (2016) 査読有り
- 22) * Matsuo K., Koizumi K., Fujita M., Morikawa T., Jo M., Shibahara N., Saiki I., Yoshie O., Nakayama T.: Efficient use of a crude drug/herb library reveals Ephedra Herb as a specific antagonist for T_H2-specific chemokine receptors CCR3, CCR4, and CCR8. *Front. Cell Dev. Biol.* 4, 54 (2016) 査読有り
- 23) * Ninomiya K., Miyazawa S., Ozeki K., Matsuo N., Muraoka O., Kikuchi T., Yamada T., Tanaka R., Morikawa T.: Hepatoprotective limonoids from andiroba (*Carapa guianensis*). *Int. J. Mol. Sci.* 17, 591 (2016) 査読有り

- 24) 小林正和、赤木淳二、山口康代、山崎寛生、森川敏生、二宮清文、吉川雅之、村岡 修: サラシアエキス末配合食品の長期摂取時および過剰摂取時の安全生の検討 -プラセボ対照二重盲検比較試験-. *Jpn. Pharmacol. Ther.* 44, 399-408 (2016) 査読有り
- 25) * Ninomiya K., Matsumoto T., Chaipech S., Miyake S., Katsuyama Y., Tsuboyama A., Pongpiriyadacha Y., Hayakawa T., Muraoka O., Morikawa T.: Simultaneous quantitative analysis of 12 methoxyflavones with melanogenesis inhibitory activity from the rhizomes of *Kaempferia parviflora*. *J. Nat. Med.* 70, 179-189 (2016) 査読有り
- 26) * Morikawa T., Ninomiya K., Kuramoto H., Kamei I., Yoshikawa M., Muraoka O.: Phenylethanoid and phenylpropanoid glycosides with melanogenesis inhibitory activity from the flowers of *Narcissus tazetta* var. *chinensis*. *J. Nat. Med.* 70, 89-101 (2016) 査読有り
- 27) * Takeda T., Tsubaki M., Sakamoto K., Ichimura E., Enomoto A., Suzuki Y., Itoh T., Imano M., Tanabe G., Muraoka O., Matsuda H., Satou T., Nishida S.: Mangiferin, a novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor growth in a mouse metastatic melanoma model. *Toxicol Appl Pharmacol.*, 306, 105-112 (2016) 査読有り
- 28) * Takeda T., Tsubaki M., Kino T., Kawamura A., Isoyama S., Itoh T., Imano M., Tanabe G., Muraoka O., Matsuda H., Satou T., Nishida S.: Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κ B pathway. *Int J Oncol.*, 48, 2704-2712 (2016) 査読有り
- 29) * Takeda T., Tsubaki M., Kino T., Yamagishi M., Iida M., Itoh T., Imano M., Tanabe G., Muraoka O., Satou T., Nishida S.: Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. *Chem Biol Interact.*, 251, 26-33 (2016) 査読有り
- 30) Takeda Y., Hayashi Y., Utamura N., Takamoto C., Kinoshita M., Yamamoto S., Hayakawa T., Suzuki S.: Capillary electrochromatography using monoamine- and triamine-bonded silica nanoparticles as pseudostationary phases. *J. Chromatogr. A*, 1427, 170-176 (2016) 査読有り
- 31) * T Tong KI., Ota K., Komuro A., Ueda T., Ito A., Koch AC., Okada H.: Attenuated DNA damage repair delays therapy-related myeloid neoplasms in a mouse model. *Cell Death and Disease*. 7(10):e240 (2016) 査読有り
- 32) * Fujita Y., Kimura M., Sato H., Takata T., Ono N., Nishio K.: Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells. *Arch Pharm Res*, 39(6), 825-32 (2016) 査読有り

テーマB: 「癌・増殖シグナル制御メカニズム解析」

- 1) Aoyama T, Fukao A, Fujiwara T.: Translational regulation is mediated by the cross-talk between the miRNA pathway and RNA binding proteins. *Nihon Yakurigaku Zasshi*. Vol 147 No. 6, pp.346-350, Jun, 2016 査読有り
- 2) Kanda Y., Satoh R., Matsumoto S., Ikeda C., Inutsuka N., Hagihara K., Matzno S., Tsujimoto S., Kita A., Sugiura R.: Skb5, an SH3 adaptor protein, regulates Pmk1 MAPK signaling by controlling the intracellular localization of the MAPKKK Mkh1. *J Cell Sci*, 129(16): 3189-3202 (2016)

- 3) Mukai H., Muramatsu A, Mashud R., Kubouchi K., Tsujimoto S., Hongu T., Kanaho Y., Tsubaki M., Nishida S., Shioi G., Danno S., Mehruba M., Satoh R., Sugiura R.: PKN3 is the major regulator of angiogenesis and tumor metastasis in mice. *Sci Rep*, 6:18979 (2016)
- 4) * Kawase A., Yamamoto T., Egashira S., Iwaki M.: Stereoselective inhibition of methotrexate excretion by glucuronides of nonsteroidal anti-inflammatory drugs via multidrug resistance protein 2 and 4. *J Pharmacol Exp Ther*, 356, 366-374 (2016) 査読有
- 5) * Kawase A., Tanaka H., Otori T., Matsuyama K., Iwaki M.: Effects of duration of phenytoin administration on mRNA expression of cytochrome P450 and P-glycoprotein in the liver and small intestine of rats. *Asian J Pharm Sci*, 11, 662-667 (2016)査読有
- 6) * Kawase A., Handa A., Iwaki M.: Effects of high-cholesterol diet on pravastatin disposition in the perfused rat liver. *Eur J Drug Metab Pharmacokine*, (2016). 査読有
- 7) Otori T, Matzno S, Kawase A, Iwaki M, Kimachi T, Nishiwaki K, Fioni W, Tominaga R, Asahide M, Nishikata M, Ishii Y, Matsuyama K.: Development of hemiacetal esterified levofloxacin to prevent chelation with metal containing drugs. *J Pharm Pharmacol*, 68, 1527-1534 (2016). 査読有り
- 8) * Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H.: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. *Drug Metab Pharmacokinet*, 31, 425-432 (2016). 査読有り
- 9) * Kawase A, Handa A, Iwaki M.: Effects of fasting on pravastatin disposition in perfused rat liver. *Int J Pharm Pharm Sci*, 8, 130-134 (2016). 査読有り
- 10) * Kawase A, Araki Y, Ueda Y, Nakazaki S, Iwaki M.: Impact of high-cholesterol diet on expression levels of niemann-pick C1-like 1 and other intestinal transporters in rats and mice. *Eur J Drug Metabol Pharmacokinet*, 41, 457-463 (2016). 査読有り
- 11) * Uraki M, Kawase A, Matsushima Y, Iwaki M.: Effects of dose, flow rate and bile acid on diclofenac disposition in the perfused rat liver. *Eur J Drug Metabol Pharmacokinet*, 41, 301-307 (2016). 査読有り
- 12) * Uraki M, Kawase A, Iwaki M.: Stereoselective hepatic disposition of ibuprofen in the perfused liver of rat with adjuvant-induced arthritis. *Xenobiotica*, In press (2016). 査読有り
- 13) Matsumura S, Murata K, Zaima N, Yoshioka Y, Morimoto M, Matsuda H, Iwaki M.: Inhibitory activities of sesame seed extract and its constituents against β -secretase. *Nat Prod Commun*, 11, 1671-1674 (2016). 査読有り
- 14) * Uraki M, Kawase A, Sayama H, Matsushima Y, Iwaki M.: Effects of adjuvant-induced inflammation on disposition of diclofenac and its metabolites in perfused rat liver. *J Pharm Sci*, In press (2016). 査読有り
- 15) Tsubaki M., Mashimo K., Takeda T., Kino T., Fujita A., Itoh T., Imano M., Sakaguchi K., Satou T., Nishida S.: Statins inhibited the MIP-1 α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells. *Biomed Pharmacother.*, 78, 23-29 (2016) 査読有り

- 16) Tsubaki M., Takeda T., Yoshizumi M., Ueda E., Itoh T., Imano M., Satou T., Nishida S.: RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines. *Tumour Biol.*, 37, 9099-9110 (2016) 査読有り
- 17) Fukami K., Sekiguchi F., Kawabata A.: Hydrogen sulfide and T-type Ca²⁺ channels in pain processing, neuronal differentiation and neuroendocrine secretion. *Pharmacology*, 99, 107-114 (2016). 査読有り
- 18) 坪田真帆、川畑篤史: 膵臓の疼痛における侵害受容体の関与と治療への展望。(特集:膵疾患の疼痛治療の up-to-date —疼痛の発生メカニズムから疾患別治療まで)。 *胆と膵*, 37, 1535-1539 (2016). 査読無し
- 19) Nishida T., Tsubota M., Kawaishi Y., Yamanishi H., Kamitani N., Sekiguchi F., Ishikura H., Liu K., Nishibori M., Kawabata A.: Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. *Toxicology*, 365, 48-58 (2016). 査読有り
- 20) Sekiguchi F., Kawara Y., Tsubota M., Kawakami E., Ozaki T., Kawaishi Y., Tomita S., Kanaoka D., Yoshida S., Ohkubo T., Kawabata A.: Therapeutic potential of RQ-00311651, a novel T-type Ca²⁺ channel blocker, in distinct rodent models for neuropathic and visceral pain. *Pain*, 157, 1655-1665 (2016). 査読有り
- 21) Mitani K., Sekiguchi F., Maeda T., Tanaka Y., Kawabata A.: The prostaglandin E2/EP4 receptor/cyclic AMP/T-type Ca²⁺ channel pathway mediates neurogenesis in sensory neuron-like ND7/23 cells. *J. Pharmacol. Sci.*, 130, 177-180 (2016). 査読有り
- 22) Sekiguchi F., Sekimoto T., Ogura A., Kawabata A.: Endogenous hydrogen sulfide enhances cell proliferation of human gastric cancer AGS cells. *Biol. Pharm. Bull.*, 39, 887-890 (2016). 査読有り
- 23) Yamasoba D., Tsubota M., Domoto R., Sekiguchi F., Nishikawa H., Liu K., Nishibori M., Ishikura H., Yamamoto T., Taga A., Kawabata A.: Peripheral HMGB1-induced hyperalgesia in mice: redox state-dependent distinct roles of RAGE and TLR4. *J. Pharmacol. Sci.*, 130, 139-142 (2016). 査読有り
- 24) Aoki Y., Tsubota M., Nishimoto Y., Maeda Y., Sekiguchi F., Kawabata A.: Selective sensitization of C-fiber nociceptors by hydrogen sulfide. *J. Pharmacol. Sci.*, 130, 38-41 (2016). 査読有り
- 25) Yamamoto S., Kinoshita M., Suzuki S.: Current landscape of protein glycosylation analysis and recent progress toward a novel paradigm of glycoscience research. *J. Pharm. Biomed. Anal.*, 130, 273-300 (2016) 査読有り
- 26) * Matsuo K., Itoh T., Koyama A., Imamura R., Kawai S., Nishiwaki K., Oiso N., Kawada A., Yoshie O., Nakayama T.: CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma. *Cancer Lett.* 378, 16-22 (2016) 査読有り
- 27) Matsuo K., Hirobe S., Okada N., Nakagawa S.: Analysis of skin permeability and toxicological properties of silica particles. *Biol. Pharm. Bull.* 39, 1201-1205 (2016) 査読有り
- 28) Matsuo K., Nishiuma S., Hasegawa S., Kawabata F., Kitahata K., Nakayama T.: Vaccination with antigen combined with ab-ATP as a vaccine adjuvant enhances antigen-specific antibody production via dendritic cell activation. *Biol. Pharm. Bull.* 39, 1073-1076 (2016) 査読有り

- 29) Moriguchi K., Miyamoto K., Tanaka N., Ueno R., Nakayama T., Yoshie O., Kusunoki S.: C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* 291, 54-58 (2016) 査読有り
- 30) Kobayashi I., Takahashi F., Nurwidya F., Murakami A., Hashimoto M., Nara T., Tajima K., Shimada N., Yoshioka Y., Sasaki S., Moriyama M., Moriyama H., Takahashi K.: Oct4 plays a crucial role in the persistence of gefitinib-resistant lung cancer stem cells. *Biochem Biophys Res Commun.* 473(1), 125-32(2016)査読有り
- 31) * Yamamoto T., Kudo M., Peng WX., Takata H., Takakura H., Teduka K., Fujii T., Mitamura K., Taga A., Uchida E., Naito Z.: Identification of aldolase A as a potential diagnostic biomarker for colorectal cancer based on proteomic analysis using formalin-fixed paraffin-embedded tissue. *Tumor Biol.* 37, 13595-13606 (2016) 査読有り
- 32) Satoh R., Ogata H., Saito T., Zhou B., Omura K., Kurabuchi S., Mitamura K., Ikegawa S., Hagey LR., Hofmann AF., Iida T.: Two Major Bile Acids in the Hornbills, (24R,25S)-3 α ,7 α ,24-Trihydroxy-5 β -cholestan-27-oyl Taurine and Its 12 α -Hydroxy Derivative. *Lipids.* 51, 757-68 (2016) 査読有り
- 33) Sato Née Okihara R., Saito T., Ogata H., Nakane N., Namegawa K., Sekiguchi S., Omura K., Kurabuchi S., Mitamura K., Ikegawa S., Raines J., Hagey LR., Hofmann AF., Iida T.: Novel, major 2 α - and 2 β -hydroxy bile alcohols and bile acids in the bile of *Arapaima gigas*, a large South American river fish. *Steroids.* 107, 112-120 (2016) 査読有り
- 34) Kanzaki A., Kudo M., Ansai SI., Peng WX., Ishino K., Yamamoto T., Wada R., Fujii T., Teduka K., Kawahara K., Kawamoto Y., Kitamura T., Kawana S., Saeki H., Naito Z.: Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma. *Int J Oncol.* 48, 1007-1015 (2016) 査読有り

テーマC: 「臨床評価・臨床腫瘍検体を用いた創薬シーズのPOC研究と個別化医療」

- 1) * Tanizaki J., Banno E., Togashi Y., Hayashi H., Sakai K., Takeda M., Kaneda H., Nishio K., Nakagawa K.: Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. *Lung Cancer*, E-pub ahead of print, (2016) 査読有り
- 2) * Mizukami T., Sakai K., Naruki S., Taniyama T., Horie Y., Izawa N., Tsuda T., Fujino T., Boku N., Yasuda H., Fukunaga T., Nakajima TE., Nishio K.: Identification of a FGFR3-TACC3 fusion in esophageal cancer. *Ann Oncol*, E-pub ahead of print, (2016) 査読有り
- 3) * Matsuo N., Azuma K., Sakai K., Hattori S., Kawahara A., Ishii H., Tokito T., Kinoshita T., Yamada K., Nishio K., Hoshino T.: Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. *lung cancer patients. Sci Rep*, E-pub ahead of print, (2016) 査読有り
- 4) * Hibi M., Kaneda H., Tanizaki J., Sakai K., Togashi Y., Terashima M., De Velasco MA., Fujita Y., Banno E., Nakamura Y., Takeda M., Ito A., Mitsudomi T., Nakagawa K., Okamoto I., Nishio K.: FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. *Cancer Sci*, 107(11), 1667-76 (2016) 査読有り

- 5) * Chiba M., Togashi Y., Tomida S., Mizuuchi H., Nakamura Y., Banno E., Hayashi H., Terashima M., De Velasco MA., Sakai K., Fujita Y., Mitsudomi T., Nishio K.: MEK inhibitors against MET-amplified non-small cell lung cancer. *Int J Oncol*, 49(6), 2236-44 (2016) 査読有り
- 6) * Shitara K., Yonesaka K., Denda T., Yamazaki K., Moriwaki T., Tsuda M., Takano T., Okuda H., Nishina T., Sakai K., Nishio K., Tokunaga S., Yamanaka T., Boku N., Hyodo I., Muro K.: A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G. *Cancer Sci*, 107(12), 1843-50 (2016) 査読有り
- 7) * De Velasco MA., Kura Y., Yoshikawa K., Nishio K., Davies BR., Uemura H.: Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. *Oncotarget*, 7(13), 15959-76 (2016) 査読有り
- 8) * Nagai H., Oiso N., Tomida S., Sakai K., Fujiwara S., Nakamachi Y., Kawano S., Kawada A., Nishio K., Nishigori C.: Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: identification of a recurrent p.P25L mutation in KRT5 in four affected family members. *Br J Dermatol*, 174(3), 633-5 (2016) 査読有り
- 9) * Kaibori M., Sakai K., Ishizaki M., Matsushima H., De Velasco MA., Matsui K., Iida H., Kitade H., Kwon AH., Nagano H., Wada H., Haji S., Tsukamoto T., Kanazawa A., Takeda Y., Takemura S., Kubo S., Nishio K.: Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. *Oncotarget*, 7(31), 49091-8 (2016) 査読有り
- 10) * Watanabe S., Takeda M., Takahama T., Iwasa T., Tsurutani J., Tanizaki J., Shimizu T., Sakai K., Wada Y., Isogai N., Nishio K., Nakagawa K.: Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease. *Invest New Drugs*, 34(3), 394-6 (2016) 査読有り
- 11) * Terashima M., Togashi Y., Sato K., Mizuuchi H., Sakai K., Suda K., Nakamura Y., Banno E., Hayashi H., De Velasco MA., Fujita Y., Tomida S., Mitsudomi T., Nishio K.: Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. *Clin Cancer Res*, 22(14), 3663-71 (2016) 査読有り
- 12) * Takegawa N., Yonesaka K., Sakai K., Ueda H., Watanabe S., Nonagase Y., Okuno T., Takeda M., Maenishi O., Tsurutani J., Satoh T., Okamoto I., Nishio K., Tamura T., Nakagawa K.: HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. *Oncotarget*, 7(3), 3453-60 (2016) 査読有り
- 13) * Murao T., Shiotani A., Fujita Y., Yamanaka Y., Kamada T., Manabe N., Hata J., Nishio K., Haruma K.: Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk. *J Gastroenterol Hepatol*, 31(1), 99-106 (2016) 査読有り
- 14) * Suda K., Murakami I., Sakai K., Tomizawa K., Mizuuchi H., Sato K., Nishio K., Mitsudomi T.: Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. *Lung Cancer*, 91, 36-40 (2016) 査読有り

- 15) * Yonesaka K., Hirotsu K., Kawakami H., Takeda M., Kaneda H., Sakai K., Okamoto I., Nishio K., Janne PA., Nakagawa K.: Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. *Oncogene*, 35(7), 878-86 (2016) 査読有り
- 16) * Ohira T., Sakai K., Matsubayashi J., Kajiwara N., Kakihana M., Hagiwara M., Hibi M., Yoshida K., Maeda J., Ohtani K., Nagao T., Nishio K., Ikeda N.: Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. *Cancer Sci*, 107(11), 1660-6 (2016) 査読有り
- 17) * Takahama T., Sakai K., Takeda M., Azuma K., Hida T., Hirabayashi M., Oguri T., Tanaka H., Ebi N., Sawa T., Bessho A., Tachihara M., Akamatsu H., Bandoh S., Himeji D., Ohira T., Shimokawa M., Nakanishi Y., Nakagawa K., Nishio K.: Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). *Oncotarget*, 7(36), 58492-9 (2016) 査読有り
- 18) * Nakamura Y., Togashi Y., Nakahara H., Tomida S., Banno E., Terashima M., Hayashi H., de Velasco MA., Sakai K., Fujita Y., Okegawa T., Nutahara K., Hamada S., Nishio K.: Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. *Mol Cancer Ther*, 15(8), 1988-97 (2016) 査読有り
- 19) * Banno E., Togashi Y., Nakamura Y., Chiba M., Kobayashi Y., Hayashi H., Terashima M., de Velasco MA., Sakai K., Fujita Y., Mitsudomi T., Nishio K.: Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? *Cancer Sci*, 107(8), 1134-40 (2016) 査読有り
- 20) * Mizuuchi H., Suda K., Murakami I., Sakai K., Sato K., Kobayashi Y., Shimoji M., Chiba M., Sesumi Y., Tomizawa K., Takemoto T., Sekido Y., Nishio K., Mitsudomi T.: Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. *Cancer Sci*, 107(4), 461-8 (2016) 査読有り
- 21) * Takeda M., Sakai K., Okamoto K., Hayashi H., Tanaka K., Shimizu T., Nishio K., Nakagawa K.: Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity. *Ann Oncol*, 27(4), 748-50 (2016) 査読有り
- 22) * Nagai T., Arao T., Nishio K., Matsumoto K., Hagiwara S., Sakurai T., Minami Y., Ida H., Ueshima K., Nishida N., Sakai K., Saijo N., Kudo K., Kaneda H., Tamura D., Aomatsu K., Kimura H., Fujita Y., Haji S., Kudo M.: Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma. *Dig Dis*, 34(6), 702-07 (2016) 査読有り
- 23) * Sato K., Suda K., Shimizu S., Sakai K., Mizuuchi H., Tomizawa K., Takemoto T., Nishio K., Mitsudomi T.: Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. *PLoS One*, 11(4), e0154186 (2016) 査読有り
- 24) * Azuma K., Hirashima T., Yamamoto N., Okamoto I., Takahashi T., Nishio M., Hirata T., Kubota K., Kasahara K., Hida T., Yoshioka H., Nakanishi K., Akinaga S., Nishio K., Mitsudomi T., Nakagawa K.: Phase II study of erlotinib plus

- tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. *ESMO Open*, 1(4), e000063 (2016) 査読有り
- 25) Kato T., Oka K., Nakamura T., Ito A.: Decreased expression of Met during differentiation in rat lung. *Eur J Histochem.* 60, 2575 (2016) 査読有り
- 26) YT Fujiwara K., Fujita Y., Kasai A., Onaka Y., Hashimoto H., Okada H., Yamashita T. Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse. *Transl Psychiatry.* 6 (e766) (2016) 査読有
- 27) Martini E., Wittkopf N., Günther C., Leppkes M., Okada H., Watson AJ., Podstawa E., Backert I., Kerstin Amann K., Markus F Neurath NF., Christoph Becker C.: Loss of surviving in intestinal epithelial progenitor cells leads to mitotic catastrophe and breakdown of gut immune homeostasis. *Cell reports.* 14 (5), 1062-1073(2016) 査読有
- 28) Sugihara M., Sadamori H., Nishibori M., Sato Y., Tazawa H., Shinoura S., Umeda Y., Yoshida R., Nobuoka D., Utsumi M., Ohno K., Nagasaka T., Yoshino T., Takahashi HK., Yagi T., Fujiwara T.: Anti-high mobility group box 1 monoclonal antibody improves ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy. *Am J Surg.* 211, 179-188 (2016) 査読有り
- 29) Izushi Y., Teshigawara K., Liu K., Wang D., Wake H., Takata K., Yoshino T., Takahashi HK., Mori S., Nishibori M.: Soluble form of the receptor for advanced glycation end-products attenuates inflammatory pathogenesis in a rat model of lipopolysaccharide-induced lung injury. *J Pharmacol Sci.* 130(4), 226-34 (2016) 査読有り
- 30) Wake H., Mori S., Liu K., Morioka Y., Teshigawara K., Sakaguchi M., Kuroda K., Gao Y., Takahashi H., Ohtsuka A., Yoshino T., Morimatsu H., Nishibori M.: Histidine-Rich Glycoprotein Prevents Septic Lethality through Regulation of Immunothrombosis and Inflammation. *EBioMedicine.* 9, 180-94 (2016) 査読有り
- 31) Haruma J., Teshigawara K., Hishikawa T., Wang D., Liu K., Wake H., Mori S., Takahashi HK., Sugi K., Date I., Nishibori M.: Anti-high mobility group box-1 (HMGB1) antibody attenuates delayed cerebral vasospasm and brain injury after subarachnoid hemorrhage in rats. *Sci Rep.* 6, 37755 (2016) 査読有
- 32) HO3) YT Fujiwara K., Fujita Y., Kasai A., Onaka Y., Hashimoto H., Okada H., Yamashita T.: Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse. *Transl Psychiatry.* 6, e766 (2016) 査読有
- 33) * Niwa A., Nishibori M., Hamasaki S., Kobori T., Liu K., Wake H., Mori S., Yoshino T., Takahashi H.: Voluntary exercise induces neurogenesis in the hypothalamus and ependymal lining of the third ventricle. *Brain Struct Funct.* 221(3), 1653-66 (2016) 査読有り

- 1) 藤原俊伸: 生化学「みにれびゅう」, 翻訳開始過程を標的とした蛋白質合成のファインチューニング, 公益社団法人日本生化学会, 88(1), pp. 135-138, 2016
- 2) 森川敏生: エバーラスティングフラワーの血糖上昇抑制作用. 波多野力, 下田博司 監修, ポリフェノール: 機能性成分研究開発の最新動向, 株式会社シーエムシー出版(東京), 2016, pp. 174-183.
- 3) 森川敏生: コンプリヘンシブ基礎化学 有機・物化・分析・薬剤を学ぶために. 大内秀一 編著, 第2, 11, 12章分筆, 京都廣川書店(東京), 2016, pp. 5-20, 167-208.
- 4) 岩城正宏: コンパス生物薬剤学(改訂第2版), 伊藤智夫編, 南江堂, 264 ページ, 2016.
- 5) 岩城正宏, 金尾義治ら: New パワーブック生物薬剤学(第3版), 廣川書店, 533 ページ, 2016
- 6) 高橋英夫, 西堀正洋 HMGB1 とその受容体型研究の現状と展望 日本臨床 2016 74(4)703-711
- 7) 富樫庸介, 西尾和人 世代別(第1, 2, 3)EGFR-TKI の耐性化機構 がん分子標的治療 14(2): 237-43, 2016.
- 8) 坂井和子, 西尾和人 【いま、がんのクリニカルシーケンスがおもしろい!】 cfDNA による遺伝子変異検出の臨床応用へ向けたデジタル PCR 技術 実験医学 34(18): 3074-3080, 2016.
- 9) 西尾和人 【肺癌診断・治療の最前線】肺癌におけるクリニカルシーケンシング 呼吸器内科 29(3): 185-90, 2016.
- 10) 西尾和人 マルチ診断薬による肺癌最適化医療に向けての取り組み 肺癌 56(1): 48-54, 2016.
- 11) 西尾和人 【婦人科がん治療の新機軸】次世代シーケンサーを用いたコンパニオン診断、クリニカルシーケンシング 産科と婦人科 83(1): 55-61, 2016.
- 12) 西尾和人, 坂井和子 Liquid biopsy による分子標的薬の治療感受性の予測 血液内科 72(1): 155-60, 2016.